These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33108639)

  • 1. Recurrent Vitreomacular Traction in a Patient Treated with Ocriplasmin: A Case Report.
    Katsanos A; Gorgoli K; Asproudis I; Stefaniotou M
    Ophthalmol Ther; 2021 Mar; 10(1):187-192. PubMed ID: 33108639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
    Chatziralli I; Theodossiadis G; Parikakis E; Datseris I; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
    Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
    Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocriplasmin in the Treatment of Vitreomacular Traction in a Patient with Central Retinal Vein Occlusion: A Case Report.
    Rosati A; Esposito RA; Mannino G; Scuderi G
    Case Rep Ophthalmol; 2018; 9(2):357-364. PubMed ID: 30140222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphological Reconstitution and Persistent Changes After Intravitreal Ocriplasmin for Vitreomacular Traction and Macular Hole.
    Zandi S; Freiberg F; Vaclavik V; Pfister IB; Traine PG; Kaya C; Michels S; Garweg JG
    J Ocul Pharmacol Ther; 2020 Mar; 36(2):126-132. PubMed ID: 31934816
    [No Abstract]   [Full Text] [Related]  

  • 6. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
    Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
    Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical Results in Ocriplasmin Candidates With Symptomatic Vitreomacular Traction Syndrome.
    Vasquez DH; Altamirano JC; Casaus A; Del Valle RA; Gonzalez R; Gonzalez-De La Rosa A; Navarro-Partida J; Vasquez MA; Santos A
    Curr Eye Res; 2018 Feb; 43(2):208-212. PubMed ID: 29111823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes.
    Sharma P; Juhn A; Houston SK; Fineman M; Chiang A; Ho A; Regillo C
    Am J Ophthalmol; 2015 May; 159(5):861-7.e2. PubMed ID: 25660387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.
    Quezada-Ruiz C; Pieramici DJ; Nasir M; Rabena M; Steinle N; Castellarin AA; Dhoot D; Couvillion S; See RF; Avery RL
    Retina; 2015 Jun; 35(6):1144-50. PubMed ID: 25961122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Initial Clinical Experiences Using Ocriplasmin for the Treatment of Vitreomacular Traction with or without a Macular Hole].
    Lenk J; Matthé E; Ventzke S; Pillunat LE; Sandner D
    Klin Monbl Augenheilkd; 2018 Jan; 235(1):73-80. PubMed ID: 28282697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional improvement assessed by multifocal electroretinogram after Ocriplasmin treatment for vitreomacular traction.
    Rossi S; Testa F; Melillo P; Orrico A; Della Corte M; Simonelli F
    BMC Ophthalmol; 2016 Jul; 16():110. PubMed ID: 27430356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complications of intravitreal ocriplasmin for vitreomacular traction and macular hole: a prospective spectral-domain optical coherence tomography study.
    Chatziralli IP; Theodossiadis GP; Parikakis E; Datseris I; Theodossiadis P
    Cutan Ocul Toxicol; 2016 Dec; 35(4):263-9. PubMed ID: 26555379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study of a single practice use of ocriplasmin in the treatment of vitreomacular traction.
    Knudsen VM; Kozak I
    Saudi J Ophthalmol; 2014 Apr; 28(2):139-44. PubMed ID: 24843308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Initial clinical experience in the treatment of vitreomacular traction and macular holes with ocriplasmin].
    Lommatzsch AP; Gutfleisch M; Dietzel M; Heimes B; Spital G; Böhme M; Bornfeld N; Pauleikhoff D
    Klin Monbl Augenheilkd; 2014 Sep; 231(9):909-14. PubMed ID: 24788606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitreomacular traction quantitative cutoffs for the assessment of resolution after ocriplasmin intravitreal treatment.
    Arrigo A; Calamuneri A; Bordato A; Aragona E; Pierro L; Bandello F; Battaglia Parodi M
    Sci Rep; 2020 Oct; 10(1):17583. PubMed ID: 33067537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subfoveal Lucency after Treatment of Vitreomacular Traction without Macular Hole in the Phase 3 Trials of Ocriplasmin Vitreolysis.
    Thomas AS; Folgar FA; Jaffe GJ; Toth CA; Mahmoud TH
    Ophthalmol Retina; 2019 Jan; 3(1):42-52. PubMed ID: 30929816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INTRAVITREAL SULFUR HEXAFLUORIDE INJECTION FOR THE TREATMENT OF VITREOMACULAR TRACTION SYNDROME.
    Day S; Martinez JA; Nixon PA; Levitan M; Dooner JW; Wong RW; Harper CA
    Retina; 2016 Apr; 36(4):733-7. PubMed ID: 26383712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?
    Hager A; Seibel I; Riechardt A; Rehak M; Joussen AM
    Br J Ophthalmol; 2015 May; 99(5):635-8. PubMed ID: 25403647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].
    Maier M; Abraham S; Frank C; Feucht N; Lohmann CP
    Ophthalmologe; 2015 Dec; 112(12):990-4. PubMed ID: 26062717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular hole.
    Bennison C; Stephens S; Lescrauwaet B; Van Hout B; Jackson TL
    J Mark Access Health Policy; 2016; 4():. PubMed ID: 27429719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.